| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0304-3959(90)90004-W |
| P953 | full work available at URL | https://journals.lww.com/10.1016/0304-3959(90)90004-W |
| P698 | PubMed publication ID | 1697056 |
| P50 | author | Russell K. Portenoy | Q112510167 |
| P2093 | author name string | Neil A. Hagen | |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neurology | Q83042 |
| Anesthesiology and pain medicine | Q26842311 | ||
| P304 | page(s) | 273-281 | |
| P577 | publication date | 1990-06-01 | |
| P1433 | published in | Pain | Q2317902 |
| P1476 | title | Breakthrough pain: definition, prevalence and characteristics | |
| P478 | volume | 41 |
| Q36832225 | A Korean Nationwide Survey for Breakthrough Cancer Pain in an Inpatient Setting |
| Q39280578 | A Novel 12-Week Study, with Three Randomized, Double-Blind Placebo-Controlled Periods to Evaluate Fentanyl Buccal Tablets for the Relief of Breakthrough Pain in Opioid-Tolerant Patients with Noncancer-Related Chronic Pain |
| Q26862553 | A comprehensive review of rapid-onset opioids for breakthrough pain |
| Q45213227 | A cross-sectional study on prevalence of pain and breakthrough pain among an unselected group of outpatients in a tertiary cancer clinic |
| Q39476625 | A device for patient-controlled intranasal analgesia (PCINA). |
| Q98154714 | A dose titration study of fentanyl buccal soluble film for breakthrough cancer pain in Taiwan |
| Q37579153 | A fixed inhaled nitrous oxide/oxygen mixture as an analgesic for adult cancer patients with breakthrough pain: study protocol for a randomized controlled trial |
| Q84617366 | A formal feasibility study of sublingual methadone for breakthrough cancer pain |
| Q39280743 | A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain |
| Q33783438 | A multidisciplinary bone metastases clinic at Toronto Sunnybrook Regional Cancer Centre - A review of the experience from 1999 to 2005. |
| Q39325643 | A new transmucosal drug delivery system for patients with breakthrough cancer pain: the fentanyl effervescent buccal tablet |
| Q35106423 | A prospective study of the pathophysiology and clinical characteristics of pain in a palliative medicine population |
| Q43413324 | A randomized controlled trial and novel mathematical analysis of the analgesic effect of oxycodone versus paracetamol orodispersible tablets |
| Q73469690 | A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain |
| Q89725639 | A randomized, double-blind, crossover, dose ranging study to determine the optimal dose of oral opioid to treat breakthrough pain for patients with advanced cancer already established on regular opioids |
| Q38952230 | A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients |
| Q39228124 | A survey of Canadian cancer patients' perspectives on the characteristics and treatment of breakthrough pain |
| Q79301299 | A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain |
| Q53265729 | A validation study of a pain classification system for advanced cancer patients using content experts: the Edmonton Classification System for Cancer Pain. |
| Q28079708 | AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions |
| Q24603566 | Abstral (Fentanyl Sublingual Tablets for Breakthrough Cancer Pain) |
| Q36431786 | Acceptability and preferences of six different routes of drug application for acute breathlessness: a comparison study between the United Kingdom and Germany |
| Q36636874 | Addiction to opioids in chronic pain patients: a literature review |
| Q43137746 | Agonist-dependent attenuation of mu-opioid receptor-mediated G-protein activation in the dorsal root ganglia of neuropathic rats |
| Q39199034 | Alberta Breakthrough Pain Assessment Tool: A validation multicentre study in cancer patients with breakthrough pain. |
| Q39283549 | An Italian survey on the attitudes in treating breakthrough cancer pain in hospice |
| Q31454907 | An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study |
| Q30395295 | Analgesia and sedation for children undergoing burn wound care |
| Q37203216 | Animal models of cancer pain |
| Q34133616 | Antalgic treatment of pain associated with bone metastases |
| Q37215376 | Assessment and management of breakthrough pain in cancer patients: current approaches and emerging research |
| Q42722974 | Assessment and treatment of breakthrough cancer pain: from theory to clinical practice |
| Q35117149 | Back to the future, current trends in breakthrough pain treatments |
| Q51270464 | Beyond the traditional definition of breakthrough pain: an observational study. |
| Q43248847 | Blessèd pain relief |
| Q34356398 | Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain |
| Q31143906 | Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS) |
| Q39152290 | Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with Cancer: Age Subgroup Analysis of a Multicenter Prospective Study |
| Q38206737 | Breakthrough cancer pain |
| Q33970064 | Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy. |
| Q36429904 | Breakthrough cancer pain - still a challenge |
| Q88320126 | Breakthrough cancer pain: The importance of the right treatment at the right time |
| Q44105804 | Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain |
| Q24633771 | Breakthrough cancer pain: review of prevalence, characteristics and management |
| Q38599605 | Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group |
| Q53288431 | Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. |
| Q34040596 | Breakthrough pain in cancer patients: new therapeutic approaches to an old challenge |
| Q33585770 | Breakthrough pain in cancer patients: pathophysiology and treatment |
| Q36057778 | Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms |
| Q44332137 | Breakthrough pain in opioid-treated chronic non-malignant pain patients referred to a multidisciplinary pain centre: a preliminary study |
| Q43568437 | Breakthrough pain in patients referred to pain clinics: the Italian pain network retrospective study |
| Q34756223 | Breakthrough pain in patients with controlled or uncontrolled basal pain: an observational study |
| Q34584282 | Breakthrough pain: assessment and management in cancer patients |
| Q51824713 | Breakthrough pain: on the road again. |
| Q35144597 | Breakthrough strong opioid analgesia prescription in patients using transdermal fentanyl admitted to a hospice |
| Q27008950 | Breast cancer pain management - a review of current & novel therapies |
| Q71558820 | Breast cancer recurrence in a patient with a previous history of radiation injury of the brachial plexus: a case report |
| Q35036692 | Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers |
| Q37407492 | Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain |
| Q64891212 | Cancer Pain Assessment and Classification. |
| Q41703866 | Cancer pain management: newer perspectives on opioids and episodic pain |
| Q39298122 | Cancer pain therapy |
| Q37764968 | Cancer pain: part 1: Pathophysiology; oncological, pharmacological, and psychological treatments: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners |
| Q38146274 | Cancer-induced bone pain: Mechanisms and models |
| Q36569562 | Cancer-related breakthrough pain |
| Q37567889 | Cancer-related pain in older adults receiving palliative care: patient and family caregiver perspectives on the experience of pain |
| Q42713126 | Cannabinoid-mediated diversity of antinociceptive efficacy of parecoxib in Wistar and Sprague Dawley rats in the chronic constriction injury model of neuropathic pain |
| Q39466839 | Causes and treatment of bone pain of malignant origin |
| Q43958691 | Change in Cancer Pain Management in Korea Between 2001 and 2006: Results of Two Nationwide Surveys |
| Q41936879 | Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care |
| Q92910003 | Characteristics of Breakthrough Pain and Its Impact on Quality of Life in Terminally Ill Cancer Patients |
| Q39170820 | Characteristics of breakthrough cancer pain and its influence on quality of life in an international cohort of patients with cancer |
| Q39195016 | Characteristics of episodic breathlessness as reported by patients with advanced chronic obstructive pulmonary disease and lung cancer: Results of a descriptive cohort study. |
| Q41244868 | Characterization of a rat model of metastatic prostate cancer bone pain |
| Q39444429 | Characterization of breakthrough pain by hospice patients and their caregivers |
| Q39850994 | Characterization of cancer-induced bone pain: an exploratory study. |
| Q39299755 | Chronic pain management |
| Q41587438 | Chronic pain states: pathophysiology and medical therapy |
| Q43469101 | Circadian variation of breakthrough pain in cancer patients |
| Q37415051 | Classification of pain in cancer patients--a systematic literature review |
| Q34641014 | Clinical and genetic factors related to cancer-induced bone pain and bone pain relief |
| Q36327481 | Clinical management of pain in advanced lung cancer |
| Q41121616 | Clinicopathologic correlates of common cancer pain syndromes |
| Q48832920 | Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain |
| Q64228185 | Comparison of analgesia, adverse effects, and quality of life in cancer patients during treatment of procedural pain with intravenous morphine, fentanyl nasal spray, and fentanyl buccal tablets |
| Q42278127 | Comparison of hydromorphone continuous subcutaneous infusion and basal rate subcutaneous infusion plus PCA in cancer pain: a pilot study |
| Q38090468 | Considerations in selecting rapid-onset opioids for the management of breakthrough pain |
| Q33842155 | Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment |
| Q47888494 | Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain |
| Q34779398 | Current aproach to cancer pain management: Availability and implications of different treatment options. |
| Q60673782 | Decreases in pain at rest and movement-related pain during zoledronic acid treatment in patients with bone metastases due to breast or prostate cancer: a pilot study |
| Q40056733 | Definition, prevalence and characteristics of sudden exhaustion: a possible syndrome of fatigue in cancer? |
| Q40607097 | Description and predictors of direct and indirect costs of pain reported by cancer patients |
| Q33766488 | Development and performance of a diagnostic/prognostic scoring system for breakthrough pain |
| Q86955641 | Diagnosis and management of breakthrough cancer pain: Have all the questions been resolved? A Delphi-based consensus assessment (DOIRON) |
| Q48199095 | Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study |
| Q42659408 | Dose proportionality of fentanyl buccal tablet in doses ranging from 600 to 1300 microg in healthy adult subjects: a randomized, open-label, four-period, crossover, single-centre study |
| Q35218790 | Drug therapy for cancer pain |
| Q75194784 | Drug therapy for cancer pain |
| Q39181539 | Effective Dose Titration of Fentanyl Sublingual Spray in Patients With Breakthrough Cancer Pain |
| Q92609980 | Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets |
| Q39328001 | Effervescent morphine results in faster relief of breakthrough pain in patients compared to immediate release morphine sulfate tablet |
| Q55389816 | Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication. |
| Q42459158 | Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial |
| Q47792205 | Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain |
| Q39223362 | Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study |
| Q39194682 | Efficacy and safety of sublingual fentanyl tablets for the management of breakthrough pain in patients with chronic musculoskeletal pain with neuropathic component: multicenter prospective study |
| Q39214375 | Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain |
| Q35727780 | Epidemiology of cancer pain and factors influencing poor pain control |
| Q34539972 | Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care |
| Q34761938 | Episodic pain in patients with advanced cancer |
| Q53489981 | Evaluating the relationship between pain presentation and health-related quality of life in outpatients with metastatic or recurrent neoplastic disease. |
| Q34421409 | Evaluation and assessment of cancer pain and cancer pain treatment. |
| Q58762663 | Evaluation of Quality of Life and Satisfaction of Patients with Neuropathic Pain and Breakthrough Pain: Economic Impact Based on Quality of Life |
| Q43164718 | Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers |
| Q30844805 | Evidence and consensus recommendations for the pharmacological management of pain in India |
| Q39277434 | Experiences of cancer patients with breakthrough pain and pharmacological treatments |
| Q38603872 | Facilitation of accurate and effective radiation therapy using fentanyl pectin nasal spray (FPNS) to reduce incidental breakthrough pain due to procedure positioning |
| Q55500110 | Factors Influencing the Clinical Presentation of Breakthrough Pain in Cancer Patients. |
| Q45019837 | Faster absorption and higher systemic bioavailability of intranasal fentanyl spray compared to oral transmucosal fentanyl citrate in healthy subjects |
| Q37784261 | Fentanyl Buccal Tablet for Breakthrough Cancer Pain: Why Titrate? |
| Q33873528 | Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study |
| Q39223824 | Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label |
| Q44342328 | Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study |
| Q39282960 | Fentanyl buccal tablet for the treatment of breakthrough pain: pharmacokinetics of buccal mucosa delivery and clinical efficacy |
| Q38264067 | Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain |
| Q36895788 | Fentanyl buccal tablet: faster rescue analgesia for breakthrough pain? |
| Q37000761 | Fentanyl buccal tablet: rapid relief from breakthrough pain |
| Q48653098 | Fentanyl buccal tablets |
| Q39257062 | Fentanyl buccal tablets for the treatment of breakthrough pain |
| Q37907299 | Fentanyl for breakthrough pain: a systematic review |
| Q38106698 | Fentanyl for the treatment of tumor-related breakthrough pain. |
| Q37879143 | Fentanyl nasal spray for the treatment of cancer pain |
| Q47729744 | Fentanyl pectin nasal spray for breakthrough cancer pain. |
| Q38394314 | Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl |
| Q39226460 | Fentanyl sublingual spray for breakthrough pain in cancer patients |
| Q42230948 | Fentanyl transmucosal tablets: current status in the management of cancer-related breakthrough pain |
| Q43284157 | Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study |
| Q39293912 | Formulations of fentanyl for the management of pain |
| Q38090292 | Genes, molecules and patients--emerging topics to guide clinical pain research |
| Q39436819 | High dose morphine use in the hospice setting. A database survey of patient characteristics and effect on life expectancy |
| Q40832811 | High transdermal fentanyl requirements in a patient with chronic cancer pain |
| Q37776493 | Idiopathic breakthrough pain: a new hypothesis |
| Q39185838 | Impact of breakthrough pain on community-dwelling cancer patients: results from the National Breakthrough Pain Study |
| Q37593370 | Impact of opioid rescue medication for breakthrough pain on the efficacy and tolerability of long-acting opioids in patients with chronic non-malignant pain |
| Q41628699 | Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain |
| Q44638919 | In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance |
| Q60673783 | Incident pain and analgesic consumption decrease after samarium infusion: a pilot study |
| Q48860696 | Initial titration with 200 μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients |
| Q89706056 | Interference with daily functioning by breakthrough pain in patients with cancer |
| Q35834670 | Intermittent cancer pain: clinical importance and an updated cancer pain classification |
| Q37355278 | Intersection of chronic pain treatment and opioid analgesic misuse: causes, treatments, and policy strategies |
| Q39491052 | Intranasal fentanyl for breakthrough cancer pain. A pilot study |
| Q37875708 | Intranasal fentanyl for pain control: current status with a focus on patient considerations |
| Q46162572 | Intranasal sufentanil for cancer-associated breakthrough pain. |
| Q47598071 | Intrathecal Hydromorphone and Bupivacaine Combination Therapy for Post-Laminectomy Syndrome Optimized with Patient-Activated Bolus Device |
| Q37089016 | Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer |
| Q37740515 | Intravenous morphine for management of cancer pain |
| Q36317288 | Latin-American guidelines for cancer pain management |
| Q39199331 | Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain. |
| Q39415383 | Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain |
| Q39268873 | Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain |
| Q34410657 | Management of breakthrough pain in children with cancer |
| Q37154731 | Management of breakthrough pain in patients with cancer. |
| Q85075620 | Management of cancer pain |
| Q33995639 | Management of cancer pain. |
| Q37998511 | Management of pain in the elderly at the end of life |
| Q41818551 | Management of predictable pain using fentanyl pectin nasal spray in patients undergoing radiotherapy |
| Q35080285 | Management of terminal cancer in elderly patients |
| Q37855651 | Managing breakthrough pain |
| Q47798840 | Matrix stimulation in cancer pain: Methodology, safety and effectiveness |
| Q41637498 | Mechanisms and management of bone pain |
| Q39156546 | Mediation of Movement-Induced Breakthrough Cancer Pain by IB4-Binding Nociceptors in Rats. |
| Q24648711 | Morphine and alternative opioids in cancer pain: the EAPC recommendations |
| Q48543715 | Movement-evoked breakthrough cancer pain despite intrathecal analgesia: a prospective series |
| Q48294458 | Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies |
| Q39476518 | Nasal delivery of fentanyl |
| Q51411890 | Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain. |
| Q37281427 | Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy |
| Q40655379 | New developments in the assessment of pain in cancer patients |
| Q39491068 | New modes of opioid administration |
| Q37912136 | Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients |
| Q36052397 | Nociception and inflammatory hyperalgesia evaluated in rodents using infrared laser stimulation after Trpv1 gene knockout or resiniferatoxin lesion |
| Q52237268 | Nursing management of the patient with bone metastases. |
| Q44345268 | OPRM1 Methylation Contributes to Opioid Tolerance in Cancer Patients |
| Q89425464 | Observational Study Evaluating the Economic Impact of Breakthrough Pain in Cancer Patients in Clinical Practice in Spain: The IMDI Study |
| Q44332933 | Opioid pharmacotherapy in terminal disease |
| Q34166977 | Opioid poorly-responsive cancer pain. Part 1: clinical considerations |
| Q34225077 | Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness |
| Q35044048 | Opioid resistance in chronic daily headache: a synthesis of ideas from the bench and bedside |
| Q43938683 | Opioid switching to methadone: a pharmacoepidemiological study from a national prescription database |
| Q24244700 | Opioids for the management of breakthrough (episodic) pain in cancer patients |
| Q37895000 | Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project |
| Q24248131 | Opioids for the management of episodic pain in cancer patients |
| Q34430627 | Opioids in chronic pain |
| Q33678609 | Opioids in pain management |
| Q36135142 | Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics |
| Q46978958 | Oral transmucosal fentanyl citrate for the treatment of breakthrough pain. Results of a non-interventional study (NIS) |
| Q36920427 | Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology |
| Q39372438 | Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study |
| Q51461213 | Oral transmucosal fentanyl citrate: a new treatment for breakthrough pain. |
| Q39403588 | Oral transmucosal fentanyl citrate: a novel agent for breakthrough pain related to cancer. |
| Q36502945 | Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics |
| Q39449130 | Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients |
| Q37994343 | Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients |
| Q30342240 | Outpatient management of sickle cell pain with chronic opioid pharmacotherapy. |
| Q58557665 | Pain Intensity Factors Changing Breakthrough Pain Prevalence in Patients with Advanced Cancer: A Secondary Analysis of a Cross-Sectional Observational International Study |
| Q36855934 | Pain Syndromes in the Cancer Patient |
| Q53390998 | Pain and health-related quality of life among cancer patients in final stage of life: a comparison between two palliative care teams |
| Q34282523 | Pain assessment and management |
| Q34231140 | Pain assessment: the cornerstone to optimal pain management |
| Q51220683 | Pain in pediatric oncology--children's and parents' perspectives. |
| Q38187973 | Pain management and wound care |
| Q34766591 | Pain management in cancer patients using a mobile app: study design of a randomized controlled trial. |
| Q36794824 | Pain management, supportive and palliative care in patients with renal cell carcinoma |
| Q34556463 | Palliative care and hospice opioid dosing guidelines with breakthrough pain (BP) doses |
| Q47821345 | Pan-European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain. |
| Q35984168 | Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain |
| Q39203354 | Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain |
| Q48015149 | Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study |
| Q37914954 | Pharmacokinetics of fentanyl buccal tablet: a pooled analysis and review |
| Q38055713 | Pharmacokinetics of non-intravenous formulations of fentanyl |
| Q37974707 | Pharmacotherapy for breakthrough cancer pain |
| Q39477920 | Pharmacotherapy of cancer pain : 2. Use of opioids |
| Q35095194 | Pharmacotherapy of cancer-related episodic pain |
| Q44030193 | Pilot dose finding study of intranasal sufentanil for breakthrough and incident cancer-associated pain |
| Q39491522 | Pitfalls in the use of opiates in treatment of cancer pain |
| Q37413148 | Poor adhesion of fentanyl transdermal patches may mimic end-of-dosage failure after 48 hours and prompt early patch replacement in hospitalized cancer pain patients |
| Q47606257 | Practice Patterns in Distinguishing Between Background Pain and Breakthrough Pain During Patient Education: a Korean Physician Survey. |
| Q34276945 | Predicting place of death of elderly cancer patients followed by a palliative care unit |
| Q43070777 | Predictive factors and opioid responsiveness in cancer pain |
| Q74317837 | Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice |
| Q35421746 | Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain |
| Q90470043 | Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study |
| Q33938153 | Randomized study of pregabalin in patients with cancer-induced bone pain |
| Q53681112 | Rapid acting fentanyl formulations in breakthrough pain in cancer. Drug selection by means of the System of Objectified Judgement Analysis. |
| Q39405158 | Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion |
| Q40484502 | Recent Advances in Cancer Pain Management |
| Q36728951 | Recognition and diagnosis of breakthrough pain |
| Q91736316 | Response to Oral Immediate-Release Opioids for Breakthrough Pain in Patients with Advanced Cancer with Adequately Controlled Background Pain |
| Q34156710 | Review article: palliative care in gynecologic oncology |
| Q39801041 | Role of intranasal fentanyl in breakthrough pain management in cancer patients |
| Q39365689 | Safety and efficacy of oral trans-mucosal fentanyl citrate in the long-term treatment of breakthrough pain in oncology patients: the ECODIR study |
| Q91461179 | Sequestration of artemin reduces inflammation-induced activation and sensitization of bone marrow nociceptors in a rodent model of carrageenan-induced inflammatory bone pain |
| Q37053311 | Single-dose fentanyl sublingual spray for breakthrough cancer pain |
| Q42675814 | Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain |
| Q34297489 | Strategies for the treatment of cancer pain in the new millennium |
| Q39181576 | Sublingual Fentanyl Tablets for Relief of Breakthrough Pain in Cancer Patients and Association with Quality-of-Life Outcomes |
| Q39294172 | Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study |
| Q44020445 | Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study |
| Q37760468 | Substance abuse in cancer pain |
| Q39253677 | Successful dose finding with sublingual fentanyl tablet: combined results from 2 open-label titration studies |
| Q45103999 | Successful use of ketamine for intractable cancer pain |
| Q34537781 | Symptom assessment and management |
| Q41313419 | Symptomatic management of the older person with cancer. |
| Q77942595 | Temporal presentation of chronic cancer pain: transitory pains on admission to a multidisciplinary pain clinic |
| Q43614975 | Temporary sedation with midazolam for control of severe incident pain |
| Q61813535 | The Circadian Rhythm of Breakthrough Pain Episodes in Terminally-ill Cancer Patients |
| Q39708643 | The Gate Theory of Pain Revisited: Modeling Different Pain Conditions with a Parsimonious Neurocomputational Model |
| Q45037862 | The MERITO Study: a multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during 'titration phase' in patients with cancer pain |
| Q36539723 | The evolution and practice of acute pain medicine |
| Q74567772 | The impact of delirium on the circadian distribution of breakthrough analgesia in advanced cancer patients |
| Q37245357 | The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. |
| Q38001278 | The management of pain in metastatic bone disease |
| Q34091706 | The management of pain in terminally ill cancer patients with difficulty swallowing |
| Q34477414 | The management of pain in the oncology patient |
| Q35805721 | The pathophysiology of cancer-induced bone pain: current understanding |
| Q38108027 | The pharmacoeconomics of breakthrough cancer pain. |
| Q34126167 | The pharmacological basis of contemporary pain management |
| Q44221667 | The prevalence of episodic pain in cancer: a survey of hospice patients on admission |
| Q36854479 | The rationale for a multimodal approach in the management of breakthrough cancer pain: a review |
| Q51927039 | The role of opioids in cancer pain management. |
| Q34752698 | The role of oral transmucosal fetanyl citrate in the management of breakthrough cancer pain |
| Q36728954 | The treatment of breakthrough pain |
| Q33561309 | The use of Instanyl® in the treatment of breakthrough pain in cancer patients: a 3-month observational, prospective, cohort study |
| Q39229449 | The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting |
| Q90600723 | The use of fentanyl in pain management in head and neck cancer patients: a narrative review |
| Q39166078 | The use of low doses of a sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids |
| Q39279541 | Time to pain relief after immediate-release morphine in episodic pain: the TIME study. |
| Q39494996 | Transdermal fentanyl for the treatment of cancer pain |
| Q38586530 | Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care |
| Q43846950 | Transmucosal fentanyl in ovarian cancer |
| Q39330526 | Treating cancer-related breakthrough pain: the oral transmucosal route |
| Q47128170 | Treatment of severe cancer pain by transdermal fentanyl |
| Q26785501 | Use of Animal Models in Understanding Cancer-induced Bone Pain |
| Q28069133 | What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion |
| Q53688489 | [Breakthrough pain and short-acting opioids]. |
| Q53691201 | [Cancer breakthrough pain. Indications for rapidly effective opioids]. |
| Q80762595 | [Cancer pain management. Basic therapy and treatment of breakthrough pain] |
| Q78066690 | [Diagnosis and treatment of chronic cancer pain (I)] |
| Q73471790 | [Difficulties in the translation of pain adjectives: the case of breakthrough pain] |
| Q82908447 | [Pain and bone metastases] |
| Q45906120 | [Rapid release fentanyl administration forms. Comments of the Working Group on Tumor Pain of the German Pain Society]. |
Search more.